|
|
| | Lasofoxifene Basic information |
| Product Name: | Lasofoxifene | | Synonyms: | Lasofoxifene Base;Lasofoxifene;(5R,6S)-;CP-336,156;(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]tetralin-2-ol;(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol;(5R-cis)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol;2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- | | CAS: | 180916-16-9 | | MF: | C28H31NO2 | | MW: | 413.55 | | EINECS: | | | Product Categories: | Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 180916-16-9.mol |  |
| | Lasofoxifene Chemical Properties |
| Melting point | 110-113°C | | Boiling point | 572.4±50.0 °C(Predicted) | | density | 1.150±0.06 g/cm3(Predicted) | | storage temp. | Refrigerator | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Solid | | pka | 10.31±0.60(Predicted) | | color | White to Off-White |
| | Lasofoxifene Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | A next-generation selective estrogen receptor modulator for treating disorders associated with increased bone turnover and osteopenia. | | Definition | ChEBI: Lasofoxifene is a member of the class of tetralins that is 5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogens at positions 5 and 6 are replaced by 4-[2-(pyrrolidin-1-yl)ethoxy]phenyl and phenyl groups, respectively (the 5R,6S-stereoisomer). It is a selective estrogen receptor modulator indicated for the prevention and treatment of osteoporosis in post-menopausal women. It has a role as an antineoplastic agent, a cardioprotective agent, an estrogen receptor agonist, an estrogen receptor antagonist and a bone density conservation agent. It is a member of tetralins, an aromatic ether, a member of naphthols and a N-alkylpyrrolidine. | | Clinical Use | Lasofoxifene is a very potent second-generation SERM currently in phase III clinical trials for the treatment and
prevention of osteoporosis in postmenopausal women. |
| | Lasofoxifene Preparation Products And Raw materials |
|